» Authors » Yuichi Ishikawa

Yuichi Ishikawa

Explore the profile of Yuichi Ishikawa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 487
Citations 17618
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ichikawa T, Kishida D, Shimojima Y, Yajima N, Oguro N, Yoshimi R, et al.
J Rheumatol . 2025 Mar; PMID: 40089302
Objective: The growing use of social networking services (SNSs) has impacted how patients with systemic lupus erythematosus (SLE) access health information, potentially influencing their interaction with healthcare providers. This study...
2.
Ishikawa Y, Iwaya Y, Kuraoka A
Cardiol Young . 2025 Mar; :1-3. PMID: 40059523
Pulmonary vasodilators increased the systemic-to-pulmonary collateral flow in two single-ventricle cases, causing haemodynamic decline. Discontinuation reversed the collateral flow and improved heart failure, highlighting the need for careful monitoring. Serial...
3.
Thunnissen E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, Minami Y, Noguchi M, et al.
Lung Cancer . 2025 Jan; 199:108060. PMID: 39793325
Objectives: Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification. Materials...
4.
Sato T, Sugiyama D, Koseki J, Kojima Y, Hattori S, Sone K, et al.
JCI Insight . 2025 Jan; 10(1. PMID: 39782686
Tumor-associated macrophages (TAMs) are one of the key immunosuppressive components in the tumor microenvironment (TME) and contribute to tumor development, progression, and resistance to cancer immunotherapy. Several reagents targeting TAMs...
5.
Tao K, Ishikawa Y, Suzuki S, Muraji S, Kuraoka A, Sato M, et al.
Int J Cardiovasc Imaging . 2024 Dec; 41(2):315-324. PMID: 39724440
Fontan-associated liver disease (FALD) may be caused by chronic liver congestion due to high central venous pressure (CVP). Recently, the usefulness of liver native T1 mapping in magnetic resonance imaging...
6.
Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, et al.
Cancer Sci . 2024 Nov; 116(2):453-461. PMID: 39572007
We investigated the effectiveness and safety of nelarabine (NEL)-combined chemotherapy for newly diagnosed adult T-cell acute lymphoblastic leukemia (T-ALL) patients. We conducted a phase II trial, T-ALL213-O, where adult T-ALL...
7.
Katayama Y, Miyawaki Y, Shidahara K, Nawachi S, Asano Y, Katsuyama E, et al.
Arthritis Res Ther . 2024 Nov; 26(1):195. PMID: 39529181
Background: Patient trust plays a central role in the patient-physician relationship. This study aimed to determine whether the number of outpatient visits with a covering rheumatologist is associated with patient...
8.
Koyama N, Ishikawa Y, Ohta H, Aoki T, Kyoyama H, Aoshiba K, et al.
Cancer Med . 2024 Oct; 13(19):e70093. PMID: 39400978
Background: Small-cell lung cancer (SCLC) shows high enhancer of zeste homolog 2 (EZH2) expressions. EZH2-mediated epigenetics promote epithelial-mesenchymal transition (EMT), enhancing invasive and metastatic potential in malignancies. MicroRNAs (miRNAs), small...
9.
Ishikawa Y
Rinsho Ketsueki . 2024 Oct; 65(9):945-953. PMID: 39358294
FLT3 mutations are the most frequently identified genetic abnormalities in adult acute myeloid leukemia (AML) patients, accounting for approximately 30%. FLT3-ITD mutation specifically is considered as a poor prognostic factor...
10.
Ishikawa Y
Int J Hematol . 2024 Oct; 120(5):525-527. PMID: 39352624
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by various molecular abnormalities that significantly impact its pathogenesis and prognosis. Currently, the prognosis of AML patients is stratified on the...